A news release issued by the Securities and Exchange Commission (SEC) on September 13, 2018 reports that the SEC has issued charges against Gregory Lemelson, a hedge fund adviser, and Lemelson Capital Management LLC, his Massachusetts-based investment advisory firm, alleging they “illegally profit[ed] from a scheme to drive down the price” of Ligan Pharmaceuticals, a…

Read More